A Phase 4 interventional study of varenicline and placebo in Smoking Cessation and Depression, sponsored by Pfizer. Completed at 41 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-04-16.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.
Among the 110 studies testing varenicline in Smoking Cessation, this one is the 27th largest by enrollment, is one of 7 that started in 2010, is one of 47 in phase 4, and was the 47th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+
University of Colorado, Denver · Sites in United States, India
Ages 18+
Johns Hopkins University · Sites in South Africa
Ages 18+
University of Maryland, Baltimore · Sites in Botswana
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 25 · Phase 3 30 · Phase 4 47
First in 2000; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 525 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 209 across the 110 interventional studies. Of the 97 that completed or were terminated, 61 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 110 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Smoking Cessation by Pfizer: none open now, none under way, none of them phase 3. Of 43 finished, 23 (53%) have results posted.
Among the 44 studies in Smoking Cessation by Pfizer, this one is the 16th largest by enrollment of the 35 interventional ones that give a count, is one of 6 that started in 2010, is one of 11 in phase 4, and was the 34th registered.
Pfizer’s Smoking Cessation studies by the year they started, since 2000.
2 of the studies testing varenicline in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05413122Phase 3Johns Hopkins UniversityEvaluating Smoking Cessation Interventions for PWH in South Africa | 2027-08-31 |
| NCT05694637University of Maryland, BaltimoreBotswana Smoking and Abstinence Reinforcement Trial | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 110 studies testing varenicline in Smoking Cessation, from their registry updates:
Among Pfizer’s 44 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: varenicline
placebo
Drug: placebo
varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
Also known as: Champix/Chantix
placebo tablets matched in appearance and dosage to varenicline tablets
Percentage of Participants With a Four-Week Continuous Quit Rate (CQR)
Percentage of participants who reported no use of nicotine-containing products by answering "No" to the nicotine use inventory (NUI) questions: 'Has the participant smoked cigarettes' and 'Has the participant used other nicotine-containing products' in the last 7 days (Week 9) or since last study visit (Week 9 through 12) confirmed by a measurement of an end-expiratory exhaled carbon monoxide (CO) measurement less than or equal to 10 parts per million (ppm).
Time frame: Week 9 through Week 12
Percentage of Participants With Continuous Abstinence Rate (CAR)
Percentage of participants who remained abstinent from the period defined as start of the primary endpoint (Week 9) through Week 24 and the end of follow-up (Week 52) by reporting no use of nicotine-containing products confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.
Time frame: Week 9 through Week 24, Week 9 through Week 52
Number of Participants With 7-day Point Prevalence (PP) of Abstinence
Number of participants reporting no use of nicotine-containing products in the last 7 days confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.
Time frame: Weeks 12, 24, 52
Number of Participants With 4-Week Point Prevalence (PP) of Abstinence
Number of participants at Week 52 visit reporting no smoking and no use of other tobacco products in the last 4 weeks confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.
Time frame: Week 52
Number of Participants With Adverse Events (Including Solicited Neuropsychiatric Adverse Events)
Adverse Event (AE):any untoward medical occurrence attributed to study drug in participant who received study drug.SAE:AE causing:death;initial/prolonged inpatient hospitalization;life-threatening experience(immediate risk of dying);persistent/significant disability/incapacity;congenital anomaly.Solicited AEs collected by semi-structured neuropsychiatric AEs interview inquiring about AEs:delusions,hallucinations,paranoia,psychosis,mania,panic,agitation,hostility,aggression,homicidal ideation. If participant had positive response,investigator determined if it met AE criteria.
Time frame: Baseline up to Week 16
Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement from baseline is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16, 24, 32, 40, 52
Number of Participants With Clinical Global Impression - Severity (CGI-S) Score
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16, 24, 32, 40, 52
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) - Total Score
Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Change: mean score at observation minus mean score at baseline.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16
Change From Baseline in Hamilton Anxiety Scale (HAM-A) - Total Score
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected. Change: mean score at observation minus mean score at baseline.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16
Change From Baseline in Barratt Impulsiveness Scale (BIS-11) - Total Score
The BIS-11 is a self-administered 30 items questionnaire to assess measure of impulsivity. Items are scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). Total score range from 30 to 120. Barratt suggested that a total score of greater than or equal to 75 could indicate an impulse-control disorder, whereas a total score in the range of 70 to 75 could indicate pathological impulsivity.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
C-SSRS assessed if participant experienced following: completed suicide (1), suicide attempt (2)(response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3)("Yes" on "preparatory acts or behavior"), suicidal ideation (4)("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").
Time frame: Baseline, Week 1 up to 30 days after Week 12 (treatment-emergent [TE]), thereafter up to Week 52 (follow-up [FU])
| Milestone | Varenicline | Placebo |
|---|---|---|
| Started | 256 | 269 |
| Completed | 175 | 179 |
| Not completed | 81 | 90 |
| Withdrew: Lost to follow-up | 12 | 13 |
| Withdrew: Withdrawal by subject | 31 | 33 |
| Withdrew: Protocol violation | 6 | 6 |
| Withdrew: Adverse event | 6 | 5 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Did not meet entrance criteria | 0 | 1 |
| Withdrew: Other | 24 | 32 |
Percentage of participants who reported no use of nicotine-containing products by answering "No" to the nicotine use inventory (NUI) questions: 'Has the participant smoked cigarettes' and 'Has the participant used other nicotine-containing products' in the last 7 days (Week 9) or since last study visit (Week 9 through 12) confirmed by a measurement of an end-expiratory exhaled carbon monoxide (CO) measurement less than or equal to 10 parts per million (ppm).
| Percentage of participants | Varenicline | Placebo |
|---|---|---|
| Percentage of Participants With a Four-Week Continuous Quit Rate (CQR) | 35.9 | 15.6 |
Percentage of participants who remained abstinent from the period defined as start of the primary endpoint (Week 9) through Week 24 and the end of follow-up (Week 52) by reporting no use of nicotine-containing products confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.
| Percentage of participants | Varenicline | Placebo |
|---|---|---|
| Week 9 through Week 24 | 25.0 | 12.3 |
| Week 9 through Week 52 | 20.3 | 10.4 |
Number of participants reporting no use of nicotine-containing products in the last 7 days confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.
| participants | Varenicline | Placebo |
|---|---|---|
| Week 12 | 118 | 54 |
| Week 24 | 80 | 49 |
| Week 52 | 73 | 47 |
Number of participants at Week 52 visit reporting no smoking and no use of other tobacco products in the last 4 weeks confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.
| participants | Varenicline | Placebo |
|---|---|---|
| Number of Participants With 4-Week Point Prevalence (PP) of Abstinence | 70 | 45 |
Adverse Event (AE):any untoward medical occurrence attributed to study drug in participant who received study drug.SAE:AE causing:death;initial/prolonged inpatient hospitalization;life-threatening experience(immediate risk of dying);persistent/significant disability/incapacity;congenital anomaly.Solicited AEs collected by semi-structured neuropsychiatric AEs interview inquiring about AEs:delusions,hallucinations,paranoia,psychosis,mania,panic,agitation,hostility,aggression,homicidal ideation. If participant had positive response,investigator determined if it met AE criteria.
| participants | Varenicline | Placebo |
|---|---|---|
| Number of Participants With Adverse Events (Including Solicited Neuropsychiatric Adverse Events) | 185 | 180 |
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement from baseline is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected
| participants | Varenicline | Placebo |
|---|---|---|
| Week 1: very much improved(n=250,263) | 1 | 2 |
| Week 1: much improved(n=250,263) | 12 | 6 |
| Week 1: minimally improved(n=250,263) | 31 | 21 |
| Week 1: no change(n=250,263) | 189 | 222 |
| Week 1: minimally worse(n=250,263) | 16 | 11 |
| Week 1: much worse(n=250,263) | 1 | 1 |
| Week 2: very much improved(n=244,255) | 2 | 1 |
| Week 2: much improved(n=244,255) | 18 | 12 |
| Week 2: minimally improved(n=244,255) | 33 | 38 |
| Week 2: no change(n=244,255) | 159 | 181 |
| Week 2: minimally worse(n=244,255) | 27 | 21 |
| Week 2: much worse(n=244,255) | 5 | 2 |
| Week 3: very much improved(n=241,248) | 10 | 4 |
| Week 3: much improved(n=241,248) | 17 | 14 |
| Week 3: minimally improved(n=241,248) | 42 | 45 |
| Week 3: no change(n=241,248) | 146 | 165 |
| Week 3: minimally worse(n=241,248) | 26 | 17 |
| Week 3: much worse(n=241,248) | 0 | 3 |
| Week 4: very much improved(n=230,245) | 8 | 6 |
| Week 4: much improved(n=230,245) | 18 | 12 |
| Week 4: minimally improved(n=230,245) | 35 | 51 |
| Week 4: no change(n=230,245) | 152 | 154 |
| Week 4: minimally worse(n=230,245) | 15 | 19 |
| Week 4: much worse(n=230,245) | 2 | 3 |
| Week 5: very much improved(n=227,233) | 13 | 9 |
| Week 5: much improved(n=227,233) | 14 | 11 |
| Week 5: minimally improved(n=227,233) | 34 | 46 |
| Week 5: no change(n=227,233) | 146 | 151 |
| Week 5: minimally worse(n=227,233) | 19 | 14 |
| Week 5: much worse(n=227,233) | 1 | 2 |
| Week 6: very much improved(n=224,226) | 11 | 6 |
| Week 6: much improved(n=224,226) | 20 | 14 |
| Week 6: minimally improved(n=224,226) | 39 | 41 |
| Week 6: no change(n=224,226) | 139 | 148 |
| Week 6: minimally worse(n=224,226) | 13 | 17 |
| Week 6: much worse(n=224,226) | 2 | 0 |
| Week 7: very much improved(n=226,226) | 19 | 9 |
| Week 7: much improved(n=226,226) | 23 | 18 |
| Week 7: minimally improved(n=226,226) | 32 | 34 |
| Week 7: no change(n=226,226) | 136 | 150 |
| Week 7: minimally worse(n=226,226) | 14 | 13 |
| Week 7: much worse(n=226,226) | 2 | 2 |
| Week 8: very much improved(n=221,217) | 19 | 12 |
| Week 8: much improved(n=221,217) | 18 | 15 |
| Week 8: minimally improved(n=221,217) | 37 | 40 |
| Week 8: no change(n=221,217) | 131 | 139 |
| Week 8: minimally worse(n=221,217) | 15 | 10 |
| Week 8: much worse(n=221,217) | 0 | 1 |
| Week 8: very much worse(n=221,217) | 1 | 0 |
| Week 9: very much improved(n=218,214) | 19 | 13 |
| Week 9: much improved(n=218,214) | 19 | 16 |
| Week 9: minimally improved(n=218,214) | 36 | 31 |
| Week 9: no change(n=218,214) | 129 | 141 |
| Week 9: minimally worse(n=218,214) | 15 | 13 |
| Week 10: very much improved(n=212,211) | 20 | 13 |
| Week 10: much improved(n=212,211) | 21 | 18 |
| Week 10: minimally improved(n=212,211) | 30 | 35 |
| Week 10: no change(n=212,211) | 124 | 133 |
| Week 10: minimally worse(n=212,211) | 16 | 11 |
| Week 10: much worse(n=212,211) | 1 | 1 |
| Week 11: very much improved(n=211,205) | 23 | 15 |
| Week 11: much improved(n=211,205) | 17 | 14 |
| Week 11: minimally improved(n=211,205) | 38 | 35 |
| Week 11: no change(n=211,205) | 120 | 129 |
| Week 11: minimally worse(n=211,205) | 13 | 10 |
| Week 11: much worse(n=211,205) | 0 | 2 |
| Week 12: very much improved(n=210,204) | 19 | 17 |
| Week 12: much improved(n=210,204) | 19 | 13 |
| Week 12: minimally improved(n=210,204) | 34 | 39 |
| Week 12: no change(n=210,204) | 127 | 124 |
| Week 12: minimally worse(n=210,204) | 11 | 11 |
| Week 13: very much improved(n=211,200) | 18 | 16 |
| Week 13: much improved(n=211,200) | 19 | 13 |
| Week 13: minimally improved(n=211,200) | 34 | 40 |
| Week 13: no change(n=211,200) | 127 | 121 |
| Week 13: minimally worse(n=211,200) | 12 | 10 |
| Week 13: much worse(n=211,200) | 1 | 0 |
| Week 16: very much improved(n=203,199) | 17 | 15 |
| Week 16: much improved(n=203,199) | 27 | 16 |
| Week 16: minimally improved(n=203,199) | 26 | 33 |
| Week 16: no change(n=203,199) | 119 | 119 |
| Week 16: minimally worse(n=203,199) | 14 | 12 |
| Week 16: much worse(n=203,199) | 0 | 4 |
| Week 24: very much improved(n=196,193) | 17 | 13 |
| Week 24: much improved(n=196,193) | 17 | 18 |
| Week 24: minimally improved(n=196,193) | 24 | 31 |
| Week 24: no change(n=196,193) | 127 | 125 |
| Week 24: minimally worse(n=196,193) | 10 | 6 |
| Week 24: much worse(n=196,193) | 1 | 0 |
| Week 32: very much improved(n=188,188) | 15 | 19 |
| Week 32: much improved(n=188,188) | 19 | 21 |
| Week 32: minimally improved(n=188,188) | 27 | 31 |
| Week 32: no change(n=188,188) | 118 | 113 |
| Week 32: minimally worse(n=188,188) | 9 | 3 |
| Week 32: much worse(n=188,188) | 0 | 1 |
| Week 40: very much improved(n=180,182) | 10 | 17 |
| Week 40: much improved(n=180,182) | 23 | 15 |
| Week 40: minimally improved(n=180,182) | 23 | 32 |
| Week 40: no change(n=180,182) | 117 | 109 |
| Week 40: minimally worse(n=180,182) | 6 | 7 |
| Week 40: much worse(n=180,182) | 0 | 2 |
| Week 40: very much worse(n=180,182) | 1 | 0 |
| Week 52: very much improved(n=178,180) | 20 | 22 |
| Week 52: much improved(n=178,180) | 20 | 13 |
| Week 52: minimally improved(n=178,180) | 25 | 26 |
| Week 52: no change(n=178,180) | 110 | 112 |
| Week 52: minimally worse(n=178,180) | 3 | 7 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected
| participants | Varenicline | Placebo |
|---|---|---|
| Baseline:Normal; Week 1:Normal (n=250,263) | 105 | 100 |
| Baseline:Borderline; Week 1:Normal (n=250,263) | 7 | 8 |
| Baseline:Mildly; Week 1:Normal (n=250,263) | 4 | 1 |
| Baseline:Moderately; Week 1:Normal (n=250,263) | 1 | 0 |
| Baseline:Normal; Week 1:Borderline (n=250,263) | 3 | 3 |
| Baseline:Borderline; Week 1:Borderline (n=250,263) | 31 | 42 |
| Baseline:Mildly; Week 1:Borderline (n=250,263) | 9 | 3 |
| Baseline:Moderately; Week 1:Borderline (n=250,263) | 2 | 3 |
| Baseline:Normal; Week 1:Mildly (n=250,263) | 0 | 2 |
| Baseline:Borderline; Week 1:Mildly (n=250,263) | 4 | 1 |
| Baseline:Mildly; Week 1:Mildly (n=250,263) | 46 | 56 |
| Baseline:Moderately; Week 1:Mildly (n=250,263) | 6 | 9 |
| Baseline:Borderline; Week 1:Moderately (n=250,263) | 1 | 2 |
| Baseline:Mildly; Week 1:Moderately (n=250,263) | 1 | 0 |
| Baseline:Moderately; Week 1:Moderately (n=250,263) | 28 | 30 |
| Baseline:Markedly; Week 1:Moderately (n=250,263) | 1 | 0 |
| Baseline:Markedly; Week 1:Markedly (n=250,263) | 1 | 3 |
| Baseline:Normal; Week 2:Normal (n=244,254) | 102 | 96 |
| Baseline:Borderline; Week 2:Normal (n=244,254) | 13 | 12 |
| Baseline:Mildly; Week 2:Normal (n=244,254) | 5 | 0 |
| Baseline: Moderately; Week 2:Normal (n=244,254) | 0 | 1 |
| Baseline:Normal; Week 2:Borderline (n=244,254) | 1 | 5 |
| Baseline:Borderline; Week 2:Borderline (n=244,254) | 22 | 37 |
| Baseline:Mildly; Week 2:Borderline (n=244,254) | 10 | 7 |
| Baseline:Moderately; Week 2:Borderline (n=244,254) | 4 | 4 |
| Baseline:Normal; Week 2:Mildly (n=244,254) | 3 | 2 |
| Baseline:Borderline; Week 2:Mildly (n=244,254) | 4 | 0 |
| Baseline:Mildly; Week 2:Mildly (n=244,254) | 40 | 48 |
| Baseline:Moderately; Week 2:Mildly (n=244,254) | 10 | 12 |
| Baseline:Markedly; Week 2:Mildly (n=244,254) | 1 | 0 |
| Baseline:Normal; Week 2:Moderately (n=244,254) | 2 | 0 |
| Baseline:Borderline; Week 2:Moderately (n=244,254) | 1 | 1 |
| Baseline:Mildly; Week 2:Moderately (n=244,254) | 2 | 2 |
| Baseline:Moderately; Week 2:Moderately (n=244,254) | 20 | 24 |
| Baseline:Markedly; Week 2:Moderately (n=244,254) | 0 | 1 |
| Baseline: Moderately; Week 2:Markedly (n=244,254) | 3 | 0 |
| Baseline:Markedly; Week 2:Markedly (n=244,254) | 1 | 2 |
| Baseline:Normal; Week 3:Normal (n=241,247) | 101 | 95 |
| Baseline:Borderline; Week 3:Normal (n=241,247) | 18 | 16 |
| Baseline:Mildly; Week 3:Normal (n=241,247) | 6 | 4 |
| Baseline:Moderately; Week 3:Normal (n=241,247) | 2 | 0 |
| Baseline:Normal; Week 3:Borderline (n=241,247) | 3 | 2 |
| Baseline:Borderline; Week 3:Borderline (n=241,247) | 16 | 34 |
| Baseline:Mildly; Week 3:Borderline (n=241,247) | 8 | 7 |
| Baseline:Moderately; Week 3:Borderline (n=241,247) | 4 | 2 |
| Baseline:Normal; Week 3:Mildly (n=241,247) | 2 | 0 |
| Baseline:Borderline; Week 3:Mildly (n=241,247) | 6 | 2 |
| Baseline:Mildly; Week 3:Mildly (n=241,247) | 42 | 42 |
| Baseline:Moderately; Week 3:Mildly (n=241,247) | 10 | 17 |
| Baseline:Markedly; Week 3:Mildly (n=241,247) | 1 | 0 |
| Baseline:Normal; Week 3:Moderately (n=241,247) | 0 | 2 |
| Baseline:Mildly; Week 3:Moderately (n=241,247) | 2 | 1 |
| Baseline:Moderately; Week 3:Moderately (n=241,247) | 19 | 20 |
| Baseline:Markedly; Week 3:Moderately (n=241,247) | 0 | 1 |
| Baseline:Moderately; Week 3:Markedly (n=241,247) | 0 | 1 |
| Baseline:Markedly; Week 3:Markedly (n=241,247) | 1 | 1 |
| Baseline:Normal; Week 4:Normal (n=230,244) | 101 | 92 |
| Baseline:Borderline; Week 4:Normal (n=230,244) | 17 | 17 |
| Baseline:Mildly; Week 4:Normal (n=230,244) | 7 | 5 |
| Baseline:Moderately; Week 4:Normal (n=230,244) | 4 | 1 |
| Baseline:Normal; Week 4:Borderline (n=230,244) | 2 | 5 |
| Baseline:Borderline; Week 4:Borderline (n=230,244) | 17 | 27 |
| Baseline:Mildly; Week 4:Borderline (n=230,244) | 8 | 7 |
| Baseline:Moderately; Week 4:Borderline (n=230,244) | 1 | 3 |
| Baseline:Normal; Week 4:Mildly (n=230,244) | 0 | 2 |
| Baseline:Borderline; Week 4:Mildly (n=230,244) | 3 | 2 |
| Baseline:Mildly; Week 4:Mildly (n=230,244) | 39 | 43 |
| Baseline:Moderately; Week 4:Mildly (n=230,244) | 11 | 15 |
| Baseline:Markedly; Week 4:Mildly (n=230,244) | 1 | 1 |
| Baseline:Borderline; Week 4:Moderately (n=230,244) | 2 | 0 |
| Baseline:Mildly; Week 4:Moderately (n=230,244) | 2 | 2 |
| Baseline:Moderately; Week 4:Moderately (n=230,244) | 12 | 2 |
| Baseline:Markedly; Week 4:Moderately (n=230,244) | 1 | 18 |
| Baseline:Borderline; Week 4:Markedly (n=230,244) | 1 | 0 |
| Baseline:Moderately; Week 4:Markedly (n=230,244) | 1 | 0 |
| Baseline:Markedly; Week 4:Markedly (n=230,244) | 0 | 2 |
| Baseline:Normal; Week 5:Normal (n=227,232) | 98 | 88 |
| Baseline:Borderline; Week 5:Normal (n=227,232) | 19 | 16 |
| Baseline:Mildly; Week 5:Normal (n=227,232) | 8 | 6 |
| Baseline:Moderately; Week 5:Normal (n=227,232) | 4 | 4 |
| Baseline:Normal; Week 5:Borderline (n=227,232) | 2 | 1 |
| Baseline:Borderline; Week 5:Borderline (n=227,232) | 13 | 30 |
| Baseline:Mildly; Week 5:Borderline (n=227,232) | 8 | 4 |
| Baseline:Moderately; Week 5:Borderline (n=227,232) | 2 | 3 |
| Baseline:Normal; Week 5:Mildly (n=227,232) | 2 | 1 |
| Baseline:Borderline; Week 5:Mildly (n=227,232) | 6 | 2 |
| Baseline:Mildly; Week 5:Mildly (n=227,232) | 36 | 39 |
| Baseline:Moderately; Week 5:Mildly (n=227,232) | 11 | 15 |
| Baseline:Markedly; Week 5:Mildly (n=227,232) | 2 | 1 |
| Baseline:Normal; Week 5:Moderately (n=227,232) | 0 | 1 |
| Baseline:Borderline; Week 5:Moderately (n=227,232) | 1 | 0 |
| Baseline:Mildly; Week 5:Moderately (n=227,232) | 2 | 4 |
| Baseline:Moderately; Week 5:Moderately (n=227,232) | 12 | 15 |
| Baseline:Markedly; Week 5:Moderately (n=227,232) | 0 | 1 |
| Baseline:Moderately; Week 5:Markedly (n=227,232) | 1 | 1 |
| Baseline:Normal; Week 6:Normal (n=224,225) | 96 | 84 |
| Baseline:Borderline; Week 6:Normal (n=224,225) | 22 | 18 |
| Baseline:Mildly; Week 6:Normal (n=224,225) | 10 | 4 |
| Baseline:Moderately; Week 6:Normal (n=224,225) | 3 | 1 |
| Baseline:Normal; Week 6:Borderline (n=224,225) | 3 | 3 |
| Baseline:Borderline; Week 6:Borderline (n=224,225) | 11 | 24 |
| Baseline:Mildly; Week 6:Borderline (n=224,225) | 6 | 7 |
| Baseline:Moderately; Week 6:Borderline (n=224,225) | 5 | 4 |
| Baseline:Normal; Week 6:Mildly (n=224,225) | 2 | 2 |
| Baseline:Borderline; Week 6:Mildly (n=224,225) | 5 | 2 |
| Baseline:Mildly; Week 6:Mildly (n=224,225) | 38 | 37 |
| Baseline:Moderately; Week 6:Mildly (n=224,225) | 8 | 15 |
| Baseline:Markedly; Week 6:Mildly (n=224,225) | 2 | 1 |
| Baseline:Normal; Week 6:Moderately (n=224,225) | 0 | 3 |
| Baseline:Borderline; Week 6:Moderately (n=224,225) | 1 | 1 |
| Baseline:Mildly; Week 6:Moderately (n=224,225) | 1 | 3 |
| Baseline:Moderately; Week 6:Moderately (n=224,225) | 10 | 14 |
| Baseline:Moderately; Week 6:Markedly (n=224,225) | 1 | 1 |
| Baseline:Markedly; Week 6:Markedly (n=224,225) | 0 | 1 |
| Baseline:Normal; Week 7:Normal (n=226,225) | 93 | 88 |
| Baseline:Borderline; Week 7:Normal (n=226,225) | 23 | 20 |
| Baseline:Mildly; Week 7:Normal (n=226,225) | 14 | 5 |
| Baseline:Moderately; Week 7:Normal (n=226,225) | 3 | 1 |
| Baseline:Normal; Week 7:Borderline (n=226,225) | 5 | 2 |
| Baseline:Borderline; Week 7:Borderline (n=226,225) | 13 | 23 |
| Baseline:Mildly; Week 7:Borderline (n=226,225) | 4 | 6 |
| Baseline:Moderately; Week 7:Borderline (n=226,225) | 5 | 8 |
| Baseline:Markedly; Week 7:Borderline (n=226,225) | 1 | 0 |
| Baseline:Normal; Week 7:Mildly (n=226,225) | 2 | 0 |
| Baseline:Borderline; Week 7:Mildly (n=226,225) | 2 | 2 |
| Baseline:Mildly; Week 7:Mildly (n=226,225) | 36 | 37 |
| Baseline:Moderately; Week 7:Mildly (n=226,225) | 10 | 10 |
| Baseline:Markedly; Week 7:Mildly (n=226,225) | 1 | 1 |
| Baseline:Normal; Week 7:Moderately (n=226,225) | 0 | 1 |
| Baseline:Borderline; Week 7:Moderately (n=226,225) | 1 | 1 |
| Baseline:Mildly; Week 7:Moderately (n=226,225) | 2 | 4 |
| Baseline:Moderately; Week 7:Moderately (n=226,225) | 10 | 14 |
| Baseline:Markedly; Week 7:Moderately (n=226,225) | 0 | 1 |
| Baseline:Moderately; Week 7:Markedly (n=226,225) | 1 | 1 |
| Baseline:Normal; Week 8:Normal (n=221,216) | 92 | 87 |
| Baseline:Borderline; Week 8:Normal (n=221,216) | 21 | 19 |
| Baseline:Mildly; Week 8:Normal (n=221,216) | 12 | 6 |
| Baseline:Moderately; Week 8:Normal (n=221,216) | 3 | 3 |
| Baseline:Normal; Week 8:Borderline (n=221,216) | 4 | 2 |
| Baseline:Borderline; Week 8:Borderline (n=221,216) | 14 | 19 |
| Baseline:Mildly; Week 8:Borderline (n=221,216) | 6 | 7 |
| Baseline:Moderately; Week 8:Borderline (n=221,216) | 7 | 5 |
| Baseline:Markedly; Week 8:Borderline (n=221,216) | 2 | 0 |
| Baseline:Normal; Week 8:Mildly (n=221,216) | 2 | 0 |
| Baseline:Borderline; Week 8:Mildly (n=221,216) | 3 | 2 |
| Baseline:Mildly; Week 8:Mildly (n=221,216) | 32 | 35 |
| Baseline:Moderately; Week 8:Mildly (n=221,216) | 9 | 13 |
| Baseline:Markedly; Week 8:Mildly (n=221,216) | 0 | 1 |
| Baseline:Normal; Week 8:Moderately (n=221,216) | 1 | 0 |
| Baseline:Mildly; Week 8:Moderately (n=221,216) | 3 | 3 |
| Baseline:Moderately; Week 8:Moderately (n=221,216) | 9 | 12 |
| Baseline:Markedly; Week 8:Moderately (n=221,216) | 0 | 1 |
| Baseline:Mildly; Week 8:Markedly (n=221,216) | 0 | 1 |
| Baseline:Moderately; Week 8:Markedly (n=221,216) | 1 | 0 |
| Baseline:Normal; Week 9:Normal (n=218,213) | 91 | 87 |
| Baseline:Borderline; Week 9:Normal (n=218,213) | 22 | 18 |
| Baseline:Mildly; Week 9:Normal (n=218,213) | 11 | 5 |
| Baseline:Moderately; Week 9:Normal (n=218,213) | 4 | 4 |
| Baseline:Normal; Week 9:Borderline (n=218,213) | 3 | 2 |
| Baseline:Borderline; Week 9:Borderline (n=218,213) | 13 | 19 |
| Baseline:Mildly; Week 9:Borderline (n=218,213) | 6 | 3 |
| Baseline:Moderately; Week 9:Borderline (n=218,213) | 6 | 8 |
| Baseline:Markedly; Week 9:Borderline (n=218,213) | 2 | 1 |
| Baseline:Normal; Week 9:Mildly (n=218,213) | 3 | 0 |
| Baseline:Borderline; Week 9:Mildly (n=218,213) | 2 | 4 |
| Baseline:Mildly; Week 9:Mildly (n=218,213) | 34 | 38 |
| Baseline:Moderately; Week 9:Mildly (n=218,213) | 10 | 9 |
| Baseline:Mildly; Week 9:Moderately (n=218,213) | 1 | 0 |
| Baseline:Moderately; Week 9:Moderately (n=218,213) | 8 | 12 |
| Baseline:Markedly; Week 9:Moderately (n=218,213) | 0 | 1 |
| Baseline:Mildly; Week 9:Markedly (n=218,213) | 1 | 1 |
| Baseline:Moderately; Week 9:Markedly (n=218,213) | 1 | 1 |
| Baseline:Normal; Week 10:Normal (n=212,210) | 88 | 85 |
| Baseline:Borderline; Week 10:Normal (n=212,210) | 20 | 21 |
| Baseline:Mildly; Week 10:Normal (n=212,210) | 13 | 5 |
| Baseline:Moderately; Week 10:Normal (n=212,210) | 7 | 5 |
| Baseline:Normal; Week 10:Borderline (n=212,210) | 5 | 1 |
| Baseline:Borderline; Week 10:Borderline (n=212,210 | 14 | 18 |
| Baseline:Mildly; Week 10:Borderline (n=212,210) | 6 | 6 |
| Baseline:Moderately; Week 10:Borderline(n=212,210) | 4 | 7 |
| Baseline:Markedly; Week 10:Borderline(n=212,210) | 2 | 1 |
| Baseline:Normal; Week 10:Mildly (n=212,210) | 1 | 1 |
| Baseline:Borderline; Week 10:Mildly (n=212,210) | 1 | 2 |
| Baseline:Mildly; Week 10:Mildly (n=212,210) | 29 | 35 |
| Baseline:Moderately; Week 10:Mildly (n=212,210) | 8 | 11 |
| Baseline:Normal; Week 10:Moderately (n=212,210) | 1 | 0 |
| Baseline:Mildly; Week 10:Moderately (n=212,210) | 3 | 1 |
| Baseline:Moderately; Week 10:Moderately(n=212,210) | 9 | 9 |
| Baseline:Markedly; Week 10:Moderately (n=212,210) | 0 | 1 |
| Baseline:Moderately; Week 10:Markedly (n=212,210) | 1 | 1 |
| Baseline:Normal; Week 11:Normal (n=211,205) | 90 | 81 |
| Baseline:Borderline; Week 11:Normal (n=211,205) | 23 | 22 |
| Baseline:Mildly; Week 11:Normal (n=211,205) | 13 | 6 |
| Baseline:Moderately; Week 11:Normal (n=211,205) | 7 | 5 |
| Baseline:Markedly; Week 11:Normal (n=211,205) | 1 | 0 |
| Baseline:Normal; Week 11:Borderline (n=211,205) | 3 | 2 |
| Baseline:Borderline; Week 11:Borderline(n=211,205) | 10 | 15 |
| Baseline:Mildly; Week 11:Borderline (n=211,205) | 6 | 3 |
| Baseline:Moderately; Week 11:Borderline(n=211,205) | 3 | 6 |
| Baseline:Markedly; Week 11:Borderline (n=211,205) | 1 | 1 |
| Baseline:Normal; Week 11:Mildly (n=211,205) | 1 | 0 |
| Baseline:Borderline; Week 11:Mildly (n=211,205) | 2 | 3 |
| Baseline:Mildly; Week 11:Mildly (n=211,205) | 30 | 34 |
| Baseline:Moderately; Week 11:Mildly (n=211,205) | 9 | 13 |
| Baseline:Normal; Week 11:Moderately (n=211,205) | 0 | 1 |
| Baseline:Mildly; Week 11:Moderately (n=211,205) | 3 | 1 |
| Baseline:Moderately; Week 11:Moderately(n=211,205) | 8 | 10 |
| Baseline:Markedly; Week 11:Moderately (n=211,205) | 0 | 1 |
| Baseline:Mildly; Week 11:Markedly (n=211,205) | 0 | 1 |
| Baseline:Normal; Week 12:Normal (n=210,203) | 89 | 79 |
| Baseline:Borderline; Week 12:Normal (n=210,203) | 23 | 22 |
| Baseline:Mildly; Week 12:Normal (n=210,203) | 13 | 6 |
| Baseline:Moderately; Week 12:Normal (n=210,203) | 6 | 8 |
| Baseline:Markedly; Week 12:Normal (n=210,203) | 1 | 0 |
| Baseline:Normal; Week 12:Borderline (n=210,203) | 4 | 2 |
| Baseline:Borderline; Week 12:Borderline(n=210,203) | 12 | 16 |
| Baseline:Mildly; Week 12:Borderline (n=210,203) | 6 | 4 |
| Baseline:Moderately; Week 12:Borderline(n=210,203) | 4 | 3 |
| Baseline:Markedly; Week 12:Borderline (n=210,203) | 1 | 1 |
| Baseline:Normal; Week 12:Mildly (n=210,203) | 0 | 2 |
| Baseline:Borderline; Week 12:Mildly (n=210,203) | 0 | 1 |
| Baseline:Mildly; Week 12:Mildly (n=210,203) | 30 | 34 |
| Baseline:Moderately; Week 12:Mildly (n=210,203) | 9 | 14 |
| Baseline:Borderline; Week 12:Moderately(n=210,203) | 0 | 1 |
| Baseline:Mildly; Week 12:Moderately (n=210,203) | 3 | 3 |
| Baseline:Moderately; Week 12:Moderately(n=210,203) | 8 | 6 |
| Baseline:Markedly; Week 12:Moderately(n=210,203) | 0 | 1 |
| Baseline:Moderately; Week 12:Markedly(n=210,203) | 1 | 0 |
| Baseline:Normal; Week 13:Normal (n=211,199) | 92 | 78 |
| Baseline:Borderline; Week 13:Normal (n=211,199) | 22 | 21 |
| Baseline:Mildly; Week 13:Normal (n=211,199) | 13 | 5 |
| Baseline:Moderately; Week 13:Normal (n=211,199) | 6 | 9 |
| Baseline:Markedly; Week 13:Normal (n=211,199) | 2 | 0 |
| Baseline:Normal; Week 13:Borderline (n=211,199) | 3 | 3 |
| Baseline:Borderline; Week 13:Borderline(n=211,199) | 11 | 17 |
| Baseline:Mildly; Week 13:Borderline (n=211,199) | 7 | 6 |
| Baseline:Moderately; Week 13:Borderline(n=211,199) | 5 | 4 |
| Baseline:Markedly; Week 13:Borderline(n=211,199) | 0 | 1 |
| Baseline:Borderline; Week 13:Mildly (n=211,199) | 0 | 3 |
| Baseline:Mildly; Week 13:Mildly (n=211,199) | 30 | 32 |
| Baseline:Moderately; Week 13:Mildly (n=211,199) | 9 | 11 |
| Baseline:Mildly; Week 13:Moderately (n=211,199) | 3 | 1 |
| Baseline:Moderately; Week 13:Moderately(n=211,199) | 7 | 7 |
| Baseline:Markedly; Week 13:Moderately(n=211,199) | 0 | 1 |
| Baseline:Moderately; Week 13:Markedly (n=211,199) | 1 | 0 |
| Baseline:Normal; Week 16:Normal (n=203,198) | 91 | 78 |
| Baseline:Borderline; Week 16:Normal (n=203,198) | 19 | 20 |
| Baseline:Mildly; Week 16:Normal (n=203,198) | 14 | 6 |
| Baseline:Moderately; Week 16:Normal (n=203,198) | 7 | 11 |
| Baseline:Markedly; Week 16:Normal (n=203,198) | 2 | 0 |
| Baseline:Normal; Week 16:Borderline (n=203,198) | 2 | 2 |
| Baseline:Borderline; Week 16:Borderline(n=203,198) | 11 | 16 |
| Baseline:Mildly; Week 16:Borderline (n=203,198) | 4 | 5 |
| Baseline:Moderately; Week 16:Borderline(n=203,198) | 2 | 2 |
| Baseline:Markedly; Week 16:Borderline (n=203,198) | 0 | 1 |
| Baseline:Normal; Week 16:Mildly (n=203,198) | 1 | 2 |
| Baseline:Borderline; Week 16:Mildly (n=203,198) | 0 | 3 |
| Baseline:Mildly; Week 16:Mildly (n=203,198) | 30 | 30 |
| Baseline:Moderately; Week 16:Mildly (n=203,198) | 11 | 8 |
| Baseline:Borderline; Week 16:Moderately(n=203,198) | 0 | 2 |
| Baseline:Mildly; Week 16:Moderately (n=203,198) | 3 | 2 |
| Baseline:Moderately; Week 16:Moderately(n=203,198) | 4 | 8 |
| Baseline:Markedly; Week 16:Moderately (n=203,198) | 0 | 1 |
| Baseline:Moderately; Week 16:Markedly (n=203,198) | 2 | 1 |
| Baseline:Normal; Week 24:Normal (n=196,192) | 88 | 78 |
| Baseline:Borderline; Week 24:Normal (n=196,192) | 18 | 19 |
| Baseline:Mildly; Week 24:Normal (n=196,192) | 15 | 6 |
| Baseline:Moderately; Week 24:Normal (n=196,192) | 5 | 8 |
| Baseline:Markedly; Week 24:Normal (n=196,192) | 2 | 0 |
| Baseline:Normal; Week 24:Borderline (n=196,192) | 0 | 3 |
| Baseline:Borderline; Week 24:Borderline(n=196,192) | 13 | 14 |
| Baseline:Mildly; Week 24:Borderline (n=196,192) | 4 | 6 |
| Baseline:Moderately; Week 24:Borderline(n=196,192) | 2 | 2 |
| Baseline:Markedly; Week 24:Borderline (n=196,192) | 0 | 1 |
| Baseline:Normal; Week 24:Mildly (n=196,192) | 2 | 1 |
| Baseline:Borderline; Week 24:Mildly (n=196,192) | 0 | 3 |
| Baseline:Mildly; Week 24:Mildly (n=196,192) | 27 | 31 |
| Baseline:Moderately; Week 24:Mildly (n=196,192) | 8 | 12 |
| Baseline:Mildly; Week 24:Moderately (n=196,192) | 4 | 0 |
| Baseline:Moderately; Week 24:Moderately(n=196,192) | 7 | 7 |
| Baseline:Markedly; Week 24:Moderately (n=196,192) | 0 | 1 |
| Baseline:Moderately; Week 24:Markedly (n=196,192) | 1 | 0 |
| Baseline:Normal; Week 32:Normal (n=188,187) | 82 | 77 |
| Baseline:Borderline; Week 32:Normal (n=188,187) | 16 | 20 |
| Baseline:Mildly; Week 32:Normal (n=188,187) | 10 | 8 |
| Baseline:Moderately; Week 32:Normal (n=188,187) | 4 | 9 |
| Baseline:Markedly; Week 32:Normal (n=188,187) | 2 | 0 |
| Baseline:Normal; Week 32:Borderline (n=188,187) | 0 | 1 |
| Baseline:Borderline; Week 32:Borderline(n=188,187) | 12 | 15 |
| Baseline:Mildly; Week 32:Borderline (n=188,187) | 9 | 7 |
| Baseline:Moderately; Week 32:Borderline(n=188,187) | 4 | 1 |
| Baseline:Markedly; Week 32:Borderline (n=188,187) | 0 | 1 |
| Baseline:Normal; Week 32:Mildly (n=188,187) | 2 | 0 |
| Baseline:Borderline; Week 32:Mildly (n=188,187) | 0 | 1 |
| Baseline:Mildly; Week 32:Mildly (n=188,187) | 28 | 29 |
| Baseline:Moderately; Week 32:Mildly (n=188,187) | 8 | 11 |
| Baseline:Markedly; Week 32:Mildly (n=188,187) | 0 | 1 |
| Baseline:Mildly; Week 32:Moderately (n=188,187) | 3 | 0 |
| Baseline:Moderately; Week 32:Moderately(n=188,187) | 7 | 5 |
| Baseline:Borderline; Week 32:Markedly (n=188,187) | 0 | 1 |
| Baseline:Moderately; Week 32:Markedly (n=188,187) | 1 | 0 |
| Baseline:Normal; Week 40:Normal (n=180,181) | 81 | 71 |
| Baseline:Borderline; Week 40:Normal (n=180,181) | 17 | 20 |
| Baseline:Mildly; Week 40:Normal (n=180,181) | 11 | 7 |
| Baseline:Moderately; Week 40:Normal (n=180,181) | 2 | 7 |
| Baseline:Markedly; Week 40:Normal (n=180,181) | 2 | 0 |
| Baseline:Normal; Week 40:Borderline (n=180,181) | 0 | 2 |
| Baseline:Borderline; Week 40:Borderline(n=180,181) | 9 | 15 |
| Baseline:Mildly; Week 40:Borderline (n=180,181) | 8 | 6 |
| Baseline:Moderately; Week 40:Borderline(n=180,181) | 4 | 2 |
| Baseline:Markedly; Week 40:Borderline (n=180,181) | 0 | 1 |
| Baseline:Normal; Week 40:Mildly (n=180,181) | 1 | 0 |
| Baseline:Borderline; Week 40:Mildly (n=180,181) | 2 | 2 |
| Baseline:Mildly; Week 40:Mildly (n=180,181) | 25 | 28 |
| Baseline:Moderately; Week 40:Mildly (n=180,181) | 11 | 12 |
| Baseline:Markedly; Week 40:Mildly (n=180,181) | 0 | 1 |
| Baseline:Normal; Week 40:Moderately (n=180,181) | 0 | 1 |
| Baseline:Mildly; Week 40:Moderately (n=180,181) | 2 | 1 |
| Baseline:Moderately; Week 40:Moderately(n=180,181) | 4 | 3 |
| Baseline:Moderately; Week 40:Markedly (n=180,181) | 1 | 2 |
| Baseline:Normal; Week 52:Normal (n=178,179) | 81 | 69 |
| Baseline:Borderline; Week 52:Normal (n=178,179) | 19 | 20 |
| Baseline:Mildly; Week 52:Normal (n=178,179) | 12 | 7 |
| Baseline:Moderately; Week 52:Normal (n=178,179) | 4 | 7 |
| Baseline:Markedly; Week 52:Normal (n=178,179) | 2 | 0 |
| Baseline:Normal; Week 52:Borderline (n=178,179) | 1 | 4 |
| Baseline:Borderline; Week 52:Borderline(n=178,179) | 8 | 14 |
| Baseline:Mildly; Week 52:Borderline (n=178,179) | 8 | 8 |
| Baseline:Moderately; Week 52:Borderline(n=178,179) | 4 | 4 |
| Baseline:Markedly; Week 52:Borderline (n=178,179) | 0 | 1 |
| Baseline:Normal; Week 52:Mildly (n=178,179) | 1 | 0 |
| Baseline:Borderline; Week 52:Mildly (n=178,179) | 0 | 2 |
| Baseline:Mildly; Week 52:Mildly (n=178,179) | 24 | 26 |
| Baseline:Moderately; Week 52:Mildly (n=178,179) | 8 | 11 |
| Baseline:Mildly; Week 52:Moderately (n=178,179) | 1 | 1 |
| Baseline:Moderately; Week 52:Moderately(n=178,179) | 4 | 4 |
| Baseline:Markedly; Week 52:Moderately (n=178,179) | 0 | 1 |
| Baseline:Moderately; Week 52:Markedly (n=178,179) | 1 | 0 |
Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Change: mean score at observation minus mean score at baseline.
| Units on a scale | Varenicline | Placebo |
|---|---|---|
| Baseline(n=256,269) | 7.6 ± 7.38 | 7.9 ± 7.51 |
| Change at Week 1(n=250,265) | -1.2 ± 3.95 | -0.6 ± 4.17 |
| Change at Week 2(n= 245, 255) | -1.0 ± 6.06 | -1.1 ± 5.33 |
| Change at Week 3(n= 241, 249) | -1.9 ± 5.19 | -1.8 ± 4.96 |
| Change at Week 4(n= 230, 246) | -2.2 ± 5.62 | -1.5 ± 5.96 |
| Change at Week 5(n=228, 235) | -2.1 ± 6.01 | -2.3 ± 6.09 |
| Change at Week 6(n=224, 227) | -2.2 ± 6.15 | -2.3 ± 5.84 |
| Change at Week 7(n=226, 227) | -2.3 ± 6.57 | -2.4 ± 5.94 |
| Change at Week 8(n=221, 218) | -2.7 ± 6.51 | -2.6 ± 6.02 |
| Change at Week 9(n=218, 216) | -2.9 ± 6.11 | -2.5 ± 6.55 |
| Change at Week 10(n=214, 212) | -2.9 ± 6.21 | -2.8 ± 6.15 |
| Change at Week 11(n= 211, 206) | -3.2 ± 6.30 | -2.9 ± 6.13 |
| Change at Week 12(n= 210, 205) | -3.4 ± 6.20 | -3.2 ± 6.34 |
| Change at Week 13(n= 211, 201) | -3.0 ± 6.39 | -3.6 ± 5.88 |
| Change at Week 16(n= 202, 197) | -3.1 ± 6.36 | -3.2 ± 6.61 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected. Change: mean score at observation minus mean score at baseline.
| Units on a scale | Varenicline | Placebo |
|---|---|---|
| Baseline(n=256,269) | 6.1 ± 5.23 | 6.4 ± 5.17 |
| Change at Week 1(n=250,265) | -0.5 ± 2.54 | -0.7 ± 3.15 |
| Change at Week 2(n= 245, 255) | -0.7 ± 3.98 | -0.5 ± 3.79 |
| Change at Week 3(n= 241, 249) | -1.3 ± 3.41 | -1.2 ± 3.68 |
| Change at Week 4(n= 230, 246) | -1.6 ± 3.72 | -1.2 ± 3.87 |
| Change at Week 5(n=228, 235) | -1.6 ± 4.05 | -1.6 ± 4.00 |
| Change at Week 6(n=224, 227) | -1.7 ± 4.03 | -1.6 ± 4.00 |
| Change at Week 7(n=226, 227) | -2.0 ± 4.40 | -1.8 ± 4.32 |
| Change at Week 8(n=221, 218) | -1.9 ± 4.65 | -1.9 ± 4.10 |
| Change at Week 9(n=218, 216) | -2.0 ± 4.40 | -1.9 ± 3.94 |
| Change at Week 10(n=214, 212) | -2.2 ± 4.24 | -2.0 ± 4.12 |
| Change at Week 11(n= 211, 206) | -2.3 ± 4.48 | -2.1 ± 4.31 |
| Change at Week 12(n= 210, 205) | -2.3 ± 4.27 | -2.4 ± 4.47 |
| Change at Week 13(n= 211, 201) | -2.4 ± 4.49 | -2.7 ± 4.34 |
| Change at Week 16(n= 202, 197) | -2.7 ± 4.67 | -2.5 ± 4.28 |
The BIS-11 is a self-administered 30 items questionnaire to assess measure of impulsivity. Items are scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). Total score range from 30 to 120. Barratt suggested that a total score of greater than or equal to 75 could indicate an impulse-control disorder, whereas a total score in the range of 70 to 75 could indicate pathological impulsivity.
| Units on a scale | Varenicline | Placebo |
|---|---|---|
| Baseline(n=256,269) | 65.1 ± 6.42 | 64.2 ± 7.30 |
| Change at Week 1(n=250,265) | -0.5 ± 4.36 | -0.8 ± 4.26 |
| Change at Week 2(n= 244, 255) | -0.8 ± 4.73 | -1.1 ± 4.83 |
| Change at Week 3(n= 241, 249) | -1.0 ± 4.75 | -1.3 ± 4.81 |
| Change at Week 4(n= 230, 246) | -1.0 ± 5.19 | -1.2 ± 4.95 |
| Change at Week 5(n=228, 234) | -1.1 ± 5.27 | -1.1 ± 5.39 |
| Change at Week 6(n=224, 226) | -1.4 ± 5.28 | -1.2 ± 5.43 |
| Change at Week 7(n=226, 227) | -1.6 ± 5.62 | -1.3 ± 6.08 |
| Change at Week 8(n=219, 216) | -1.3 ± 5.81 | -1.2 ± 6.54 |
| Change at Week 9(n=218, 215) | -1.5 ± 6.25 | -1.4 ± 6.24 |
| Change at Week 10(n=214, 211) | -1.5 ± 6.13 | -1.7 ± 6.94 |
| Change at Week 11(n= 211, 205) | -1.6 ± 6.24 | -1.5 ± 6.78 |
| Change at Week 12(n= 210, 204) | -1.0 ± 6.55 | -1.4 ± 7.31 |
| Change at Week 13(n= 211, 201) | -1.4 ± 6.52 | -1.1 ± 7.00 |
| Change at Week 16(n= 202, 196) | -1.4 ± 6.25 | -1.3 ± 6.85 |
C-SSRS assessed if participant experienced following: completed suicide (1), suicide attempt (2)(response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3)("Yes" on "preparatory acts or behavior"), suicidal ideation (4)("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").
| participants | Varenicline | Placebo |
|---|---|---|
| Baseline,Suicidal Behavior or/and Ideation | 6 | 1 |
| Baseline,4 | 6 | 1 |
| Baseline,4: wish to be dead | 6 | 1 |
| TE,Suicidal Behavior or/and Ideation | 15 | 20 |
| TE,2 | 0 | 1 |
| TE,4 | 15 | 19 |
| TE,4: wish to be dead | 15 | 18 |
| TE,4: non-specific active suicidal thoughts | 4 | 7 |
| TE,4: with any methods,without intent to act | 2 | 5 |
| TE,4: with some intent,without specific plan. | 0 | 3 |
| TE,4: with specific plan and intent | 0 | 1 |
| FU,Suicidal Behavior or/and Ideation | 13 | 12 |
| FU,1 | 1 | 0 |
| FU,4 | 12 | 12 |
| FU,4: wish to be dead | 11 | 12 |
| FU,4: non-specific active suicidal thoughts | 5 | 3 |
| FU,4: with any methods,without intent to act | 2 | 2 |
| FU,4: with some intent,without specific plan | 1 | 1 |
| FU,7 | 1 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline | — | 7/256 (2.7%) | 158/256 (61.7%) |
| Placebo | — | 7/269 (2.6%) | 126/269 (46.8%) |
| Event | Varenicline | Placebo |
|---|---|---|
| PalpitationsCardiac disorders | 1/256 | 0/269 |
| Acute abdomenGastrointestinal disorders | 1/256 | 0/269 |
| Autoimmune hepatitisHepatobiliary disorders | 1/256 | 0/269 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/256 | 0/269 |
| Ligament laxityMusculoskeletal and connective tissue disorders | 1/256 | 0/269 |
| Depression suicidalPsychiatric disorders | 1/256 | 1/269 |
| Intentional sefl-injuryPsychiatric disorders | 1/256 | 1/269 |
| Psychotic disorderPsychiatric disorders | 1/256 | 0/269 |
| Claculus uretericRenal and urinary disorders | 1/256 | 0/269 |
| Haemodynamic instabilityVascular disorders | 1/256 | 0/269 |
| Event | Varenicline | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 69/256 | 28/269 |
| HeadacheNervous system disorders | 43/256 | 30/269 |
| Abnormal dreamsPsychiatric disorders | 29/256 | 22/269 |
| IrritabilityGeneral disorders | 28/256 | 22/269 |
| InsomniaPsychiatric disorders | 28/256 | 13/269 |
| AnxietyPsychiatric disorders | 18/256 | 25/269 |
| Dry mouthGastrointestinal disorders | 17/256 | 14/269 |
| AgitationPsychiatric disorders | 17/256 | 10/269 |
| DepressionPsychiatric disorders | 17/256 | 13/269 |
| DiarrhoeaGastrointestinal disorders | 16/256 | 12/269 |
| Age, Customized(participants) | Varenicline | Placebo | Total |
|---|---|---|---|
| 18 to 44 years | 106 | 98 | 204 |
| 45 to 64 years | 146 | 160 | 306 |
| Greater than or equal to 65 years | 4 | 11 | 15 |
| Sex: Female, Male(Participants) | Varenicline | Placebo | Total |
|---|---|---|---|
| Female | 159 | 170 | 329 |
| Male | 97 | 99 | 196 |
The record gives a start of Mar 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline